Primary Objective: To determine the efficacy of Gefitinib in NSCLC patient harboring a positive EGFR mutation.
Secondary Objective: To evaluate the subjective response of NSCLC patients harboring a positive EGFR mutation who treated with Gefitinib.
Safety Objective: To evaluate the safety and tolerability of Gefitinib in NSCLC patient harboring a positive EGFR mutation.
Age
16–70
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
NSCLC based on histopathologic examination
Adenocarcinoma and/or nonadenocarcinoma based on histology examination
Clinical stadium stage IIIB and IV
Age 16-70 years old
Received gefitinib as therapy
At least completed 2 (two) data sets of RECIST 1.1 evaluations during the study period from January 2013 until July 2015
You may not be if
Missing data of any variables of the treatment outcomes in the medical record
Clareo Health | The Evaluation of Lung Cancer Patient Treated With Epidermal Growth Factor Receptor Tyrosine Kinase
